Status:
UNKNOWN
Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer
Lead Sponsor:
Shanghai 10th People's Hospital
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Lung cancer is the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery. Mitochondria-targete...
Eligibility Criteria
Inclusion
- The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good.
- Patients with single nodule.
- Before IIB period according to the eighth edition of the TNM staging period.
- No mediastinal lymph node metastasis.
- No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.
- Eastern Cooperative Oncology Group performance status of 0 to 1
- Sufficient organ functions
Exclusion
- Active bacterial or fungous infection.
- Simultaneous or metachronous (within the past 5 years) double cancers.
- Patients with contraindications to radiofrequency ablation and inability to complete treatment;
- Women during pregnancy or breast-feeding.
- Uncontrollable diabetes mellitus.
- Patients with severe heart, lung, kidney disease or other systemic diseases who have been judged to have a severe impact on survival or who are pre-assessed to be unable to tolerate thoracoscopic surgery
Key Trial Info
Start Date :
January 31 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
1753 Patients enrolled
Trial Details
Trial ID
NCT03840408
Start Date
January 31 2019
End Date
January 31 2024
Last Update
February 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai 10th People's Hospital
Shanghai, Shanghai Municipality, China, +86200072